HCV Next Current Issue

The following articles appeared in the print edition of HCV Next.

Table of Contents

• Diabetes and HCV: Unraveling a Complicated Relationship
• A Conversation with Donald M. Jensen, MD
• An Overlooked Overlap Syndrome Neha Nigam, MD; James H. Lewis, MD, FACP, FACG, AGAF
• A Still-Unraveling Connection Creates Heated Debate
• Clustering Prevalent Among Injection Drug Users with HCV in Vancouver
• Depression, Illness, Uncertainty Evident in Chronic HCV Patients on Watchful Waiting
• HCV Core-Antigen Test Cheaper, Quicker Than RNA
• Networking Strategy May Decrease HCV Prevalence Among Injection Drug Users
• Survival Among HCV Patients with SVR Reaches that of General Population
• Check Hep C Program Effective in Identifying HCV in New York
• C-WORTHY: Grazoprevir/Elbasvir Regimen Yielded High SVR Rates in Patients with HCV Genotype 1
• Decreased Hemoglobin Levels Did Not Impact SVR Rate in Patients with HCV Genotype 1
• DAA Regimen Led to High SVR in Patients with HCV Genotype 1b
• Markers Accurate in Detecting Cirrhosis in Patients with HCV
• UNITY 2: Fixed-Dose Combination with BMS-791325 Yields SVR12 in Treatment-Naive, Experienced Patients
• The Liver Meeting 2014
• FDA Approves Simeprevir to be Used with Sofosbuvir for HCV Genotype 1
• MicroRNA Therapeutic Decreased Viral Load in Patients with Various HCV Genotypes
• New Drug Application for Asunaprevir Withdrawn in US
• Specialists Anticipate Preference for Newly Approved Combination to Treat HCV
• Treatment of HCV Following Liver Transplantation in the Era of Direct-Acting Antivirals Stevan A. Gonzalez, MD, MS